EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Prostate Cancer

Ruben Raychaudhuri, Daniel W Lin, R Bruce Montgomery

JAMA · 22.04.2025 · 333 (16) · 1433

DOI: 10.1001/jama.2025.0228 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift JAMA, erschienen am 22.04.2025. Verfasst von Ruben Raychaudhuri und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Washington, Seattle. Hauptthemen laut MEDLINE: Adenocarcinoma, Prostatic Neoplasms. Die Arbeit wurde bisher 420-mal zitiert (Crossref) und nennt 114 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Prostate cancer is the most common nonskin cancer in men in the US, with an estimated 299 010 new cases and 35 250 deaths in 2024. Prostate cancer is the second most common cancer in men worldwide, with 1 466 680 new cases and 396 792 deaths in 2022. Observations The most common type of prostate cancer is adenocarcinoma (≥99%), and the median age at diagnosis is 67 years. More than 50% of prostate cancer risk is attributable to genetic factors; older age and Black race (annual incidence rate, 173.0 cases per 100 000 Black men vs 97.1 cases per 100 000 White men) are also strong risk factors. Recent guidelines encourage shared decision-making for prostate-specific antigen (PSA) screening. At diagnosis, approximately 75% of patients have cancer localized to the prostate, which is associated with a 5-year survival rate of nearly 100%. Based on risk stratification that incorporates life expectancy, tumor grade (Gleason score), tumor size, and PSA level, one-third of patients with localized prostate cancer are appropriate for active surveillance with serial PSA measurements, prostate biopsies, or magnetic resonance imaging, and initiation of treatment if the Gleason score or tumor stage increases. For patients with higher-risk disease, radiation therapy or radical prostatectomy are reasonable options; treatment decision-making should include consideration of adverse events and comorbidities. Despite definitive therapy, 2% to 56% of men with localized disease develop distant metastases, depending on tumor risk factors. At presentation, approximately 14% of patients have metastases to regional lymph nodes. An additional 10% of men have distant metastases that are associated with a 5-year survival rate of 37%. Treatment of metastatic prostate cancer primarily relies on androgen deprivation therapy, most commonly through medical castration with gonadotropin-releasing hormone agonists. For patients with newly diagnosed metastatic prostate cancer, the addition of androgen receptor pathway inhibitors (eg, darolutamide, abiraterone) improves survival. Use of abiraterone improved the median overall survival from 36.5 months to 53.3 months (hazard ratio, 0.66 [95% CI, 0.56-0.78]) compared with medical castration alone. Chemotherapy (docetaxel) may be considered, especially for patients with more extensive disease. Conclusions and Relevance Approximately 1.5 million new cases of prostate cancer are diagnosed annually worldwide. Approximately 75% of patients present with cancer localized to the prostate, which is associated with a 5-year survival rate of nearly 100%. Management includes active surveillance, prostatectomy, or radiation therapy, depending on risk of progression. Approximately 10% of patients present with metastatic prostate cancer, which has a 5-year survival rate of 37%. First-line therapies for metastatic prostate cancer include androgen deprivation and novel androgen receptor pathway inhibitors, and chemotherapy for appropriate patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdenocarcinomaProstatic NeoplasmsAgedHumansMaleAndrogen AntagonistsNeoplasm GradingProstate-Specific AntigenProstatectomyRisk FactorsWatchful WaitingProstateMass ScreeningEarly Detection of CancerSurvival RateAge FactorsAndrostenesBiopsy, Large-Core NeedleMagnetic Resonance Imaging

Substanzen

Androgen AntagonistsProstate-Specific AntigenabirateroneAndrostenes

Autor:innen und Institutionen

  • Department of Medicine, University of Washington, Seattle.
  • Fred Hutchinson Cancer Center, Seattle, Washington.
  • Department of Urology, University of Washington, Seattle.
  • VA Puget Sound Health Care System, Seattle, Washington.

Zitieren

APA

Raychaudhuri, R., Lin, D. W., & Montgomery, R. B. (2025). Prostate Cancer. JAMA, 333(16), 1433. https://doi.org/10.1001/jama.2025.0228

Vancouver

Raychaudhuri R, Lin DW, Montgomery RB. Prostate Cancer. JAMA. 2025;333(16):1433. doi:10.1001/jama.2025.0228

BibTeX
@article{Raychaudhuri2025,
  author = {Raychaudhuri, Ruben and Lin, Daniel W and Montgomery, R Bruce},
  title = {Prostate Cancer},
  journal = {JAMA},
  year = {2025},
  volume = {333},
  number = {16},
  pages = {1433},
  doi = {10.1001/jama.2025.0228}
}
Kostenlos starten →